Swedish Orphan Biovitrum AB (publ) BIOVF
45.72 USD 0.00 (+0.00%)
At closeNov 4, 2026, 4:00 PM EST
46.00 Day range 46.00
34.88 52-week range 49.03
- YTD
- +29.69%
- 1 year
- +31.06%
- Market cap
- 15.91B
- EPS (ttm)
- 2.02
- P/E ratio
- 22.63
- YTD return
- +29.69%
- 1-year return
- +31.06%
- Volume
- 102
- Avg volume
- 326
- Open
- 46.00
- Previous close
- 45.72
- Day's range
- 46.00 – 46.00
- 52-week range
- 34.88 – 49.03
- Earnings date
- Oct 27, 2026
2Y +14.34 (+45.70%)
Next earnings
Oct 27, 2026
Expected Oct 27, 2026. Consensus EPS estimate 0.63.
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Oct 27, 2026 | Sep 30, 2026 | 0.63 | — | — | — |
| Jul 16, 2026 | Jun 30, 2026 | 0.38 | 0.3288 | -0.05 | -13.47% |
| Apr 28, 2026 | Mar 31, 2026 | 0.3821 | 0.45 | +0.07 | +17.77% |
| Feb 5, 2026 | Dec 31, 2025 | 0.4567 | 0.60 | +0.14 | +31.38% |
| Oct 20, 2025 | Sep 30, 2025 | 0.4925 | 0.64 | +0.15 | +29.95% |
| Jul 16, 2025 | Jun 30, 2025 | 0.177 | 0.24 | +0.06 | +35.59% |
News
Swedish Orphan Biovitrum (BIOVF) Tops Q3 Earnings and Revenue Estimates 
Earnings Preview: Swedish Orphan Biovitrum (BIOVF) Q3 Earnings Expected to Decline 
Swedish Orphan Biovitrum (OTCMKTS:BIOVF) Receives Consensus Recommendation of “Moderate Buy” from Analysts 
Swedish Orphan Biovitrum (OTCMKTS:BIOVF) Sees Large Decline in Short Interest 
Swedish Orphan Biovitrum (OTCMKTS:BIOVF) Short Interest Update 
Swedish Orphan Biovitrum AB (publ) (SWOBY) Q1 2026 Earnings Call Transcript 
Notice of Annual General Meeting in Swedish Orphan Biovitrum AB (publ) 
Swedish Orphan Biovitrum AB (publ) (SWOBY) Analyst/Investor Day Transcript 
Swedish Orphan Biovitrum AB (publ) (SWOBY) Q4 2025 Earnings Call Transcript 
Reviewing Swedish Orphan Biovitrum (OTCMKTS:BIOVF) & Astria Therapeutics (NASDAQ:ATXS)
Your note
Sign in to keep a note on BIOVF — it syncs with the Stock Master app.